The Cancer Institute is a leader in cutting-edge treatments. Using a truly multidisciplinary approach, patients have access to advanced diagnostics, minimally invasive surgical interventions, and personalized genomic and immune-oncologic treatment options. Our team of cancer specialists – many of whom completed fellowships and specialty training at prestigious academic centers – offers comprehensive services for individuals with a cancer diagnosis.

Follow

Submissions from 2022

Link

Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation, Meghan C. Thompson, Krish Patel, Neil Bailey, and See all authors in comments

Link

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer., James T Topham, Chris J O'Callaghan, Harriet Feilotter, Hagen F Kennecke, Young S Lee, Weimin Li, Kimberly C Banks, Katie Quinn, Daniel J Renouf, Derek J Jonker, Dongsheng Tu, Eric X Chen, and Jonathan M Loree

Cell transfer therapy targeting mutated neoantigens in epithelial cancer, E Tran

Targeting mutant KRAS with adoptive T-cell therapy, E Tran

Targeting mutant KRAS with TCR-gene therapy, E Tran

TCR-gene therapy targeting mutant KRAS, E Tran

Targeting mutant KRAS with TCR-gene therapy, Eric Tran

TILs Update, Eric Tran

Link

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply., Eric Tran, Walter Urba, and Rom Leidner

Link

Routine frozen section during pancreaticoduodenectomy does not improve value-based care, Abhineet Uppal, Wade O Christopher, Trang Nguyen, Brooke Vuong, Stacey Stern, Juan Mejia, Roshanthi Weerasinghe, Evan Ong, and Anton J Bilchik

Link

The TARGIT-A Randomized Trial: TARGIT-IORT Versus Whole Breast Radiation Therapy: Long-Term Local Control and Survival., Jayant S Vaidya, Max Bulsara, Frederik Wenz, Elena Sperk, Samuele Massarut, Michael Alvarado, Norman R Williams, Chris Brew-Graves, Marcelle Bernstein, Dennis Holmes, Lorenzo Vinante, Steffi Pigorsch, Steinar Lundgren, Valery Uhl, David Joseph, Jeffrey S Tobias, and TARGIT-A authors

Link

Editorial: Mechanisms of Lymphocyte Exclusion in the Tumor Microenvironment., Rieneke van de Ven, Carlo Bifulco, Jason J Luke, and Sarah E Church

Link

Neoantigen-specific CD4 + T cells in human melanoma have diverse differentiation states and correlate with CD8 + T cell, macrophage, and B cell function, Joshua R Veatch, Sylvia M Lee, Carolyn Shasha, Naina Singhi, Julia L Szeto, Ata S Moshiri, Teresa S Kim, Kimberly Smythe, Paul Kong, Matthew Fitzgibbon, Brenda Jesernig, Shailender Bhatia, Scott S Tykodi, Evan T Hall, David R Byrd, John A Thompson, Venu G Pillarisetty, Thomas Duhen, A McGarry Houghton, Evan Newell, Raphael Gottardo, and Stanley R Riddell

Link

Robotic vs laparoscopic nephroureterectomy for upper tract urothelial carcinoma: a multicenter propensity-score matched pair "tetrafecta" analysis (ROBUUST collaborative group)., Alessandro Veccia, Umberto Carbonara, Hooman Djaladat, Reza Mehrazin, Daniel Eun, Adam C Reese, Xiaosong Meng, Robert Uzzo, Abhishek Srivastava, James R Porter, Jason Farrow, Marcus Jamil, Giuseppe Rosiello, Riccardo Tellini, Andrea Mari, Ali Al-Qathani, Koon Ho Rha, Linhui Wang, Riccardo Mastroianni, Matteo Ferro, Ottavio De Cobelli, Kevin Hakimi, Fabio Crocerossa, Alireza Ghoreifi, Giovanni Cacciamani, Amit Amit S Bhattu, Alexandre Mottrie, Firas Abdollah, Andrea Minervini, Zhenjie Wu, Giuseppe Simone, Ithaar H Derweesh, Mark L Gonzalgo, Vitaly Margulis, Chandru P Sundaram, and Riccardo Autorino

Link

CTNI-51. FEASIBILITY AND SAFETY OF NEUROSURGICAL RESECTION AND INTRA-OPERATIVE RADIATION THERAPY USING THE XOFT AXXENT ELECTRONIC BRACHYTHERAPY SYSTEM AND BEVACIZUMAB IN RECURRENT GLIOBLASTOMA, Naveed Wagle, Garni Barkhoudarian, Lisa Chaiken, Robert Wollman, Akanksha Sharma, Jose Carrillo, Minhdan Nguyen, Judy D Truong, Jared Chow, Emma Chacon, and Santosh Kesari

Geno4ME: establishment of an equitable whole-genome sequencing-based platform for clinical screening in a large healthcare system, Josiah Wagner, I A. Lucas-Beckett, K R. Emery, B A. Cosgrove, John T. Welle, K Jade, N D. Wagner, J Rinaldi, Lindsay Dickey, K G. Jones, L Yuan, E M. Shull, J Clemens, Keri Vartanian, A T. Magis, M B. Campbell, Brian Piening, Carlo Bifulco, and Ora K. Gordon

Clinical Performance of Comprehensive Genomic Profiling Using a Wide Range of Input Quantities and Solid Tumor Tissue Types, Josiah Wagner, S Reynolds, A Dowdell, E Shull, J Welle, M Pukay, R Rattray, C Moung-Wen, T Ward, M Campbell, C Bifulco, and B Piening

Link

Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer., Evan Walgama, Naifa Busaidy, and Mark Zafereo

Link

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study., Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn, Peter A McSweeney, David B Miklos, John M Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R Shen, Rubina Siddiqi, Ioana Kloos, and Patrick M Reagan

PDF

Why so Shocky?? A case of refractory shock, Brittney Ward, Cicily Hummer, and Joseph Bell

Streamlining Solid Tumor Comprehensive Genomic Profiling Workflows Using Learned Variant and Sequencing Noise Autoclassification, Thomas Ward, S Reynolds, J Wagner, N Naidoo, E Shull, John Welle, R Rattray, C Moung-Wen, Mary Campbell, Brian Piening, and Carlo Bifulco

Link

Identification of clinically actionable biomarkers via routine comprehensive genomic profiling across a large community health system, Roshanthi Weerasinghe, Ryan Meng, Alexa K Dowdell, Bela Bapat, Ann Vita, Brock Schroeder, Alisha Stein, Lauren Harold, Mark Schmidt, Shu-Ching Chang, Thomas R. Ward, Josiah T Wagner, Stanley Piotrowski, Phillip G. Febbo, Carlo Bifulco, and Brian D. Piening

Identification of clinically actionable biomarkers via routine comprehensive genomic profiling across a large community health system., Rosohanthi K. Weersinghe, Ryan Meng, Alexa K. Dowdell, Bela Bapat, Ann Vita, Brock Schroeder, Alisha Stein, Lauren Harold, Mark Schmidt, Shu-Ching Chang, Thomas Ward, Josiah Wagner, Stanley Piotrowski, Phillip G. Febbo, Carlo Bifulco, and Brian Piening

Link

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy., Joanne Weidhaas, Nicholas Marco, Aaron W Scheffler, Anusha Kalbasi, Kirk Wilenius, Emily Rietdorf, Jaya Mini Gill, Mara Heilig, Caroline Desler, Robert K Chin, Tania Kaprealian, Susan McCloskey, Ann Raldow, Naga P Raja, Santosh Kesari, Jose Carrillo, Alexandra Drakaki, Mark Scholz, and Donatello Telesca

Enriching for tumor-reactive CD8 TIL using CD39/103 markers: Clinical implications, A Weinberg

Isolating/Expanding the Entire TIL Repertoire of Tumor-Reactive CD8 T Cells for Cell Therapy in H&N Cancer, Andrew Weinberg

Identifying tumor-reactive CD8+ TIL in patients with solid malignancies: clinical implications, Andrew D Weinberg

T Cell Agonists, Andrew D Weinberg

Accepting social e-cigarette behaviors among fraternity members found utilizing egocentric network analysis, AC Welch, MS Patterson, Candice L. Wilshire, H Kathuria, CR Gilbert, and JA Gorden

The role of ego networks for college fraternity members who use e-cigarettes, AC Welch, MS Patterson, Candice L. Wilshire, H Kathuria, CR Gilbert, and JA Gorden

Link

Design and Validation of a Whole-Genome Sequencing- Based Assay for Population Health, John Welle, Brian D. Piening, Josiah T Wagner, Isabelle Lucas-Beckett, T Ward, Benjamin Cosgrove, Eric Shull, R Rattray, Marina Pukay, M Ricks, Kimberly K Childers, Jennifer M Linehan, Mary Campbell, Ora K Gordon, and Carlo Bifulco

Design and Validation of a Whole-Genome SequencingBased Assay for Population Health, John Welle, Brian Piening, Josiah Wagner, I Lucas-Beckett, Thomas Ward, B Cosgrove, Eric Shull, R Rattray, Marina Pukay, Milena Ricks, K Childers, J Linehan, M Campbell, Ora Gordon, and Carlo Bifulco

Link

Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy., Di Wen, Tingxizi Liang, Guojun Chen, Hongjun Li, Zejun Wang, Jinqiang Wang, Ruxing Fu, Xiao Han, Tianyuan Ci, Yuqi Zhang, Peter Abdou, Ruoxin Li, Linlin Bu, Gianpietro Dotti, and Zhen Gu

Link

778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors, Breelyn Wilky, Kim Margolin, Rachel E Sanborn, Steven O'Day, and See full list of authors in comments

Link

Comparing Initial Surgery versus Fibrinolytics for Pleural Space Infections: A Retrospective Multicenter Cohort Study., Candice L. Wilshire, Anee Sophia Jackson, Austin M Meggyesy, Kerrie E Buehler, Shu-Ching Chang, Leah C Horslen, Joshua R Rayburn, Carson C Fuller, Alexander S Farivar, Adam J Bograd, Brian Louie, Eric Vallieres, Ralph W Aye, Christopher R Gilbert, and Jed A Gorden

Lower paraspinous muscle index at first thoracentesis is associated with poor survival in non-small cell lung cancer, Candice L. Wilshire, AM Meggyesy, JA Gorden, and CR Gilbert

Link

Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes., Solomon L Woldu, Craig Labbate, Katie S Murray, Kyle Rose, Wade Sexton, Isamu Tachibana, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Jennifer Linehan, Alan Nieder, Marc A Bjurlin, Mitchell Humphreys, Saum Ghodoussipor, Marcus L Quek, Michael O'Donnell, Brian H Eisner, Adam S Feldman, Surena F Matin, and Yair Lotan

Link

Current Clinical Trial Landscape of OX40 Agonists., Rashi Yadav and William L. Redmond

Link

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial., Tomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely, Amanda Hayman, David O'Brien, Rehan Ahmad, Jeffrey V Manchio, Nathaniel E Fox, Kayla McCarty, Michaela Phillips, Evelyn Brosnan, Gina Vaccaro, Rui Li, Miklos Simon, Eric Bernstein, Mary McCormick, Lena Yamasaki, Yaping Wu, Ashley Drokin, Trevor Carnahan, Yy To, William L. Redmond, Brian Lee, Jeannie Louie, Eric Hansen, Matthew C Solhjem, Julie Cramer, Walter Urba, Michael J. Gough, Marka R Crittenden, and Kristina H Young

Link

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial., Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Antonio Cubillo Gracian, Anthony B El-Khoueiry, Bruno Sangro, Tarek E Eldawy, Jordi Bruix, Giovanni Luca Frassineti, Gina Vaccaro, Marina Tschaika, Christian Scheffold, Petra Koopmans, Jaclyn Neely, and Fabio Piscaglia

Link

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study., Habte Yimer, Jason Melear, Edward Faber, William Bensinger, John M Burke, Mohit Narang, Don Stevens, Kathleen S Gray, Yana Lutska, Padma Bobba, Keqin Qi, Daniela Hoehn, Ming Qi, Thomas S Lin, and Robert M Rifkin

Link

The landscape of brain tumor mimics in neuro-oncology practice., Lalanthica V Yogendran, Tuba Kalelioglu, Joseph H Donahue, Haroon Ahmad, Kester A Phillips, Nicole M Calautti, Maria-Beatriz Lopes, Ashok R Asthagiri, Benjamin Purow, David Schiff, Sohil H Patel, and Camilo E Fadul

Link

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study., Benoit You, Christopher Purdy, Larry J Copeland, Elizabeth M Swisher, Michael A Bookman, Gini Fleming, Robert Coleman, Leslie M Randall, Krishnansu S Tewari, Bradley J Monk, Robert S Mannel, Joan L Walker, Fabio Cappuccini, David Cohn, Mahvish Muzaffar, David Mutch, Andrea Wahner-Hendrickson, Lainie Martin, Olivier Colomban, and Robert A Burger

Link

A phase II trial of TGFβ type I receptor inhibitor, galunisertib, plus neoadjuvant chemoradiation in patients with locally advanced rectal cancer., Kristina H Young, Walter Urba, Michael J. Gough, Marka R Crittenden, and See full list of authors in comments

Link

Surgical approach to pediatric mediastinal masses based on imaging characteristics., Stephanie Young, R Luke Rettig, Ian V Hutchinson, Michael G Sutcliffe, and Roman M Sydorak

Link

1171 CAN1012: a selective and potent TLR7 agonist with strong antitumoral properties mediated by localized innate immune activation, Henry Yu, William L. Redmond, Yoshinobu Koguchi, and See all authors in comments

Link

Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers., Chunhong Zheng, Joseph N Fass, Yi-Ping Shih, Andrew J Gunderson, Nelson Sanjuan Silva, Huayu Huang, Brady M Bernard, Venkatesh Rajamanickam, Joseph Slagel, Carlo B Bifulco, Brian Piening, Pippa H A Newell, Paul D Hansen, and Eric Tran

Submissions from 2021

Link

Transition Therapy: Tackling the Ecology of Tumor Phenotypic Plasticity., Guim Aguadé-Gorgorió, Stuart Kauffman, and Ricard Solé

Link

Listeria monocytogenes-infected human monocytic derived dendritic cells activate Vγ9Vδ2 T cells independently of HMBPP production., Alejandro F Alice, Gwen Kramer, Shelly Bambina, Keith S Bahjat, Michael J Gough, and Marka R Crittenden

Link

Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies., John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, Krish Patel, Jeff P Sharman, William G Wierda, Michael Y Choi, Susan M O'Brien, Mazyar Shadman, Matthew S Davids, John M Pagel, Habte A Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L Combs, Judith A Fox, Richard R Furman, and Jennifer R Brown

Link

The American Society of Pain and Neuroscience (ASPN) Best Practices and Guidelines for the Interventional Management of Cancer-Associated Pain., Mansoor M Aman, Ammar Mahmoud, Timothy Deer, Dawood Sayed, Jonathan M Hagedorn, Shane E Brogan, Vinita Singh, Amitabh Gulati, Natalie Strand, Jacqueline Weisbein, Johnathan H Goree, Fangfang Xing, Ali Valimahomed, Daniel J Pak, Antonios El Helou, Priyanka Ghosh, Krishna Shah, Vishal Patel, Alexander Escobar, Keith Schmidt, Jay Shah, Vishal Varshney, William Rosenberg, and Sanjeet Narang

Link

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration., Kenneth C Anderson, Daniel Auclair, Stacey J Adam, Amit Agarwal, Melissa Anderson, Herve Avet-Loiseau, Mark Bustoros, Jessica Chapman, Dana E Connors, Ajeeta Dash, Alessandra Di Bacco, Ling Du, Thierry Facon, Juan Flores-Montero, Francesca Gay, Irene M Ghobrial, Nicole J Gormley, Ira Gupta, Howard Higley, Jens Hillengass, Bindu Kanapuru, Dickran Kazandjian, Gary J Kelloff, Ilan R Kirsch, Brandon E Kremer, Ola Landgren, Elizabeth D Lightbody, Oliver C Lomas, Sagar Lonial, Maria Victoria Mateos, Rocio Montes de Oca, Lata Mukundan, Nikhil C Munshi, Elizabeth K O'Donnell, Alberto Orfao, Bruno Paiva, Reshma Patel, Trevor J Pugh, Karthik Ramasamy, Jill Ray, Mikhail Roshal, Jeremy A Ross, Caroline C Sigman, Katie L Thoren, Suzanne Trudel, Gary A Ulaner, Nancy Valente, Brendan M Weiss, Elena Zamagni, and Shaji K Kumar

Link

Persistent N2 Following Induction Is Not a Contraindication to Surgery for Lung Cancer., Weston G Andrews, Brian Louie, Massimo Castiglioni, Ankit Dhamija, Alexander S Farivar, Joshua Chansky, Peter T White, Ralph W Aye, Eric Vallieres, and Adam J Bograd

Link

Implications of Adverse Biological Factors and Management of Solitary Fibrous Tumors of the Pleura., Weston G Andrews and Eric Vallières

Link

Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma., Robert H I Andtbacka, Brendan Curti, Gregory A Daniels, Sigrun Hallmeyer, Eric D Whitman, Jose Lutzky, Lynn E Spitler, Karl Zhou, Praveen K Bommareddy, Mark Grose, Meihua Wang, Cai Wu, and Howard L Kaufman

Link

Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer., Rebecca C Arend, Bradley J Monk, Thomas J Herzog, Kathleen N Moore, Ronnie Shapira-Frommer, Jonathan A Ledermann, Krishnansu S Tewari, Angeles Alvarez Secord, Tamar Rachmilewitz Minei, Laurence S Freedman, Austin Miller, Shifra Fain Shmueli, Michal Lavi, and Richard T Penson

Link

iNetModels 2.0: an interactive visualization and database of multi-omics data., Muhammad Arif, Cheng Zhang, Xiangyu Li, Cem Güngör, Buğra Çakmak, Metin Arslantürk, Abdellah Tebani, Berkay Özcan, Oğuzhan Subaş, Wenyu Zhou, Brian Piening, Hasan Turkez, Linn Fagerberg, Nathan Price, Leroy Hood, Michael Snyder, Jens Nielsen, Mathias Uhlen, and Adil Mardinoglu

Link

Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy)., Paolo A Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A Emens, Robert Ferris, Silvia C Formenti, Jerome Galon, Samir N Khleif, Tomas Kirchhoff, Jennifer McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M Paulos, Janis M Taube, John Timmerman, Bernard A Fox, Patrick Hwu, and Igor Puzanov

Link

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)., Paolo A Ascierto, Christian Blank, Reinhard Dummer, Marc S Ernstoff, Soldano Ferrone, Bernard A Fox, Thomas F Gajewski, Claus Garbe, Patrick Hwu, Pawel Kalinski, Michelle Krogsgaard, Roger S Lo, Jason J Luke, Bart Neyns, Michael A Postow, Sergio A Quezada, Michele W L Teng, Giorgio Trinchieri, Alessandro Testori, Corrado Caracò, Iman Osman, Igor Puzanov, and Magdalena Thurin

Link

The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020., Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, Olivera J Finn, John Goldberg, Francesco Perrone, Ryan J Sullivan, Bernard A Fox, Patrick Hwu, and Igor Puzanov

Link

The State of Melanoma: Emergent Challenges and Opportunities., Michael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, Susan M Swetter, Hensin Tsao, Julio A Aguirre-Ghiso, Maria S Soengas, Ashani T Weeraratna, Keith T Flaherty, Meenhard Herlyn, Jeffrey A Sosman, Hussein A Tawbi, Anna C Pavlick, Pamela B Cassidy, Sunandana Chandra, Paul B Chapman, Adil Daud, Zeynep Eroglu, Laura K Ferris, Bernard A Fox, Jeffrey E Gerhsenwald, Geoffrey T Gibney, Douglas Grossman, Brent A Hanks, Douglas Hanniford, Eva Hernando, Joanne M Jeter, Douglas B Johnson, Samir N Khleif, John M Kirkwood, Sancy A Leachman, Darren Mays, Kelly C Nelson, Vernon K Sondak, Ryan J Sullivan, and Glenn Merlino

Link

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134, Michael B. Atkins, Brendan Curti, and See full list of authors in comments

Link

Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma., Hani Babiker, Irene Brana, Daruka Mahadevan, Taofeek Owonikoko, Emiliano Calvo, Danny Rischin, Victor Moreno, Kyriakos P Papadopoulos, Marka Crittenden, Silvia Formenti, Jordi Giralt, Pilar Garrido, Ainara Soria, Asunción Hervás-Morón, Kosalai Kal Mohan, Matthew Fury, Israel Lowy, Melissa Mathias, Minjie Feng, Jingjin Li, and Elizabeth Stankevich

Link

Arginase therapy combines effectively with checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth., Mark D Badeaux, Annah S Rolig, Giulia Agnello, Danlee Enzler, Melissa Kasiewicz, Leslie Priddy, Jason F Wiggins, Alexander Muir, Mark R Sullivan, Jessica Van Cleef, Christopher Daige, Matthew G Vander Heiden, Venkatesh Rajamanickam, James Wooldridge, William L. Redmond, and Scott W Rowlinson

Link

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy, Keith Sadoon Bahjat, Helena Maria Hoen, Yoshinobu Koguchi, and Alan J. Korman

Link

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy, Keith Sandoon Bahjat, Helena Maria Hoen, Yoshinobu Koguchi, and Alan J. Korman

Link

Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Neil Bailey, Tenzin Tsomo, Tori Braun, Jennie Szeto, William Bensinger, Daniel N Egan, Raya Mawad, Livia Hegerova, Gayle Funk, Joanna Fesler, Megumi Bailey, John M Pagel, and Krish Patel

PDF

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy., Peng Bai, Yongzheng Li, Qiuping Zhou, Jiaqi Xia, Peng-Cheng Wei, Hexiang Deng, Min Wu, Sanny K Chan, John W Kappler, Yu Zhou, Eric Tran, Philippa Marrack, and Lei Yin

Link

Prevalence and Correlates of Successful Smoking Cessation in Bladder Cancer Survivors., Jeffrey C Bassett, Richard S Matulewicz, Lorna Kwan, William J McCarthy, John L Gore, and Christopher S Saigal

Link

A national database propensity score-matched comparison of minimally invasive and open colectomy for long-term opioid use., Amir L Bastawrous, Kara K Brockhaus, Melissa I Chang, Gediwon Milky, I-Fan Shih, Yanli Li, and Robert K Cleary

Link

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response., Joshua Bauml, Byoung Chul Cho, Rachel E Sanborn, and See full author list in comments

Link

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update., Nancy N Baxter, Erin B Kennedy, Emily Bergsland, Jordan Berlin, Thomas J George, Sharlene Gill, Philip J Gold, Alex Hantel, Lee Jones, Christopher Lieu, Najjia Mahmoud, Arden M Morris, Erika Ruiz-Garcia, Y Nancy You, and Jeffrey A Meyerhardt

Link

Identifying breast cancer recurrence histories via patient-reported outcomes., J David Beatty, Qin Sun, Daniel Markowitz, Jessica Chubak, Bin Huang, and Ruth Etzioni

Link

The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer., Anil Belur Nagaraj, Matthew Knarr, Sreeja Sekhar, R Shae Connor, Peronne Joseph, Olga Kovalenko, Alexis Fleming, Arshia Surti, Elmar Nurmemmedov, Luca Beltrame, Sergio Marchini, Michael Kahn, and Analisa DiFeo

The virtual molecular tumor board as a tool for the delivery of precision oncology, Carlo Bifulco

10. Dendritic cell migration is required for the immunological responsiveness of tumors to radiation therapy, TC Blair, G Kramer, S Bambina, A Dowdell, AF Alice, Brian D. Piening, Marka R Crittenden, and MJ Gough

Link

Minimally invasive esophagectomy., Adam J Bograd and Daniela Molena

Link

Salvage Pulmonary Resections After Definitive Chemoradiotherapy., Adam J Bograd and Eric Vallieres

Link

DNA Damage Response in Glioblastoma: Mechanism for Treatment Resistance and Emerging Therapeutic Strategies., Alipi Bonm and Santosh Kesari

Link

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data., Daniela A Bota, Warren Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Ileana Elias, Steven D Reich, Nancy Levin, Mohit Trikha, and Annick Desjardins

Link

Impact of rurality on melanoma diagnosis in Utah., Tawnya L Bowles, Carol Sweeney, John Snyder, Jesse Gygi, Brad Bott, Daniel Wray, Timothy J Yeatman, and William T Sause

Link

Merkel cell carcinoma can be indolent: A case with 7 locoregional recurrences over 15 years highlights the importance of patient-tailored management., Alyssa Breneman, Tomoko Akaike, Kelly G Paulson, Debra L Breneman, and Paul Nghiem

Link

165 Generating enhanced tumor infiltrating lymphocytes through microfluidic cell squeezing, Devin Bridgen, Andrew D Weinberg, and See full list of authors in comments

Link

A Randomized Study of Lenvatinib 18 mg Vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer., Marcia S Brose, Yury Panaseykin, Bhavana Konda, Christelle de La Fouchardiere, Brett G M Hughes, Andrew G Gianoukakis, Young Joo Park, Ilia Romanov, Monika K Krzyzanowska, Sophie Leboulleux, Terri A Binder, Corina Dutcus, Ran Xie, and Matthew H Taylor

Link

Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry., Daniel Brown, Henry Krebs, Jayson Brower, Ryan O'Hara, Eric Wang, Kirubahara Vaheesan, Liping Du, Lea Matsuoka, Donna D'Souza, Daniel Y Sze, Jafar Golzarian, Ripal Gandhi, and Andrew Kennedy

Link

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients., Jennifer R Brown, John C Byrd, Paolo Ghia, Jeff P Sharman, Peter Hillmen, Deborah M Stephens, Clare Sun, Wojciech Jurczak, John M Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, and Richard R Furman

Link

Imaging Administrators: The Overlooked Barrier to Lung Cancer Screening Implementation., Kerrie E Buehler, Candice L. Wilshire, Christopher R Gilbert, and Jed A Gorden

Link

A case of metachronous bilateral secretory carcinoma., Jessica Burlile, Andrea Collins, Joaquin Garcia, Kristin Gendron, Danielle Cunningham, and Robert Foote

PDF

The benefits of fasting for patients who are immunocompromised and undergoing cancer treatment: An integrative research review, Lori Burnett

Link

A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors., Howard A. Burris III, Alexander I. Spira, and Matthew H Taylor

Link

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia., John C Byrd, Jennifer A Woyach, Richard R Furman, Peter Martin, Susan O'Brien, Jennifer R Brown, Deborah M Stephens, Jacqueline Barrientos, Stephen Devereux, Peter Hillmen, John M Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, and William George Wierda

Link

Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells., Danda Chapagai, Gurusankar Ramamoorthy, Jessy Varghese, Elmar Nurmemmedov, Campbell McInnes, and Michael D Wyatt

Link

Portable air-fed cold atmospheric plasma device for postsurgical cancer treatment., Guojun Chen, Zhitong Chen, Zejun Wang, Richard Obenchain, Di Wen, Hongjun Li, Richard E Wirz, and Zhen Gu

Link

Impact of new cancer therapies on outpatient treatment delivery for colorectal cancer: A population-based study., Leo Chen, Caroline H Speers, Winson Y Cheung, John J Spinelli, and Hagen F Kennecke

Link

Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, A Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial., K Kent Chevli, Neal D Shore, Andrew Trainer, Angela B Smith, Daniel Saltzstein, Yaron Ehrlich, Jay D Raman, Boris Friedman, Richard D'Anna, David Morris, Brian Hu, Mark Tyson, Alexander Sankin, Max Kates, Jennifer Linehan, Douglas Scherr, Steven Kester, Michael Verni, Karim Chamie, Lawrence Karsh, Arnold Cinman, Andrew Meads, Soumi Lahiri, Madlen Malinowski, Nimrod Gabai, Sunil Raju, Mark Schoenberg, Elyse Seltzer, and William C Huang

Link

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer., R Connor Chick, G Travis Clifton, Diane F Hale, Timothy J Vreeland, Annelies T Hickerson, Phillip M Kemp Bohan, Patrick M McCarthy, Jennifer K Litton, Gheath Alatrash, Rashmi K Murthy, Na Qiao, Anne Philips, Jason Lukas, Jarrod P Holmes, Elizabeth A Mittendorf, and George E Peoples

Link

Undifferentiated Carcinoma With Osteoclast-Like Giant Cells of the Pancreas Discovered on Positron Emission Tomography Performed for Lymphoma Staging., Wade O Christopher, Trevan D Fischer, and Anton J Bilchik

Link

SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology., Ugonma N Chukwueke, Elizabeth Vera, Alvina Acquaye, Shawn L Hervey-Jumper, Yazmin Odia, Laura J Klesse, Erin Dunbar, Akanksha Sharma, Ekokobe Fonkem, Alissa A Thomas, Tamra E Werbowetski-Ogilvie, Sandra Camelo-Piragua, Na Tosha N Gatson, Macarena I de la Fuente, Terri S Armstrong, Alyx B Porter, and Sadhana Jackson

Link

P2-14-07. Marrow-infiltrating lymphocytes as adoptive immunotherapy for breast cancer, Brie Chun, Nicole E. Fredich, David B Page, and See all authors in comments

Link

94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC), Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather McArthur, and David B Page